Glaucoma Risk: New Polygenic Scores Offer Personalized Estimates

The landscape of glaucoma care is poised for a significant shift, driven by advances in genomics and the development of polygenic risk scores (PGS). These scores, which assess an individual’s genetic predisposition to the disease, could offer more personalized estimates of risk and potentially lead to earlier diagnosis and intervention. While current clinical risk factors – such as eye pressure and family history – have limitations in predicting who will develop sight-threatening glaucoma, researchers are increasingly focused on the heritable and largely polygenic, nature of the condition.

Understanding Glaucoma’s Genetic Complexity

Glaucoma isn’t a single disease, but rather a group of conditions that damage the optic nerve, often linked to elevated pressure inside the eye. Primary open-angle glaucoma (POAG) is the most common form. The disease is a leading cause of irreversible blindness worldwide, affecting tens of millions globally. Early therapeutic intervention can prevent vision loss, but relies heavily on timely diagnosis. The challenge lies in identifying those at highest risk before significant damage occurs. The high degree to which genetics influence glaucoma – its heritability – makes it a prime candidate for genetic risk prediction. However, the risk isn’t determined by a single gene, but by the combined effect of many genetic variants, hence the term “polygenic.”

A polygenic risk score isn’t a simple yes/no answer about whether someone will develop glaucoma. Instead, it’s a number reflecting the cumulative effect of numerous genetic variations, each contributing a small amount to overall risk. Researchers analyze a person’s genome, identifying these variations and weighting them based on their association with glaucoma in large population studies. The resulting score provides a relative risk estimate, indicating how much more or less likely an individual is to develop the disease compared to the average population. Recent research highlights the potential of these scores to significantly improve glaucoma screening and management.

The Promise of Polygenic Risk Scores: Recent Findings

A study published in 2024 assessed the clinical utility of a polygenic risk score for diagnosing primary open-angle glaucoma. Medscape Medical News reports that this is the first study to evaluate the score’s usefulness in a clinical setting. The research, detailed in publications like the Annual Review of Genomics and Human Genetics, builds on genome-wide association studies (GWAS) that have identified numerous genetic variants associated with glaucoma risk. GWAS involve scanning the genomes of large groups of people, comparing those with glaucoma to those without, to pinpoint common genetic differences.

The development of PGS instruments represents a significant step forward. However, it’s crucial to understand the limitations. Currently, these scores aren’t perfect predictors. They provide a probability, not a certainty. Factors beyond genetics – lifestyle, environmental exposures, and other medical conditions – also play a role in glaucoma development. The accuracy of PGS can vary across different ethnic groups, as genetic architectures can differ between populations. This highlights the need for diverse datasets in the development and validation of these scores.

How PGS Might Change Clinical Practice

The integration of PGS into clinical practice isn’t expected to be immediate or universal. Instead, a phased approach is more likely. Initially, PGS may be used to refine risk stratification, helping clinicians identify individuals who would benefit most from more frequent eye exams and closer monitoring. For example, someone with a high PGS and other risk factors (like family history or elevated eye pressure) might be screened annually, while someone with a low PGS and no other risk factors might be screened less frequently.

PGS could also play a role in clinical trials, helping to identify individuals at higher risk of disease progression, making them ideal candidates for testing new therapies. As our understanding of the genetic basis of glaucoma improves, PGS may turn into more accurate and personalized, potentially leading to the development of targeted therapies that address the underlying genetic causes of the disease.

Current Limitations and Ongoing Research

While promising, the clinical application of PGS for glaucoma faces several hurdles. One key challenge is the need for larger and more diverse datasets to improve the accuracy and generalizability of the scores. Current scores are primarily based on data from individuals of European ancestry, and their performance in other populations remains uncertain. Ongoing research is focused on addressing this disparity by including more diverse genetic data in PGS development.

Another limitation is the relatively modest predictive power of current PGS. While they can improve risk stratification, they don’t perfectly identify all individuals who will develop glaucoma. This means that PGS should be used in conjunction with other clinical risk factors, not as a standalone diagnostic tool. Researchers are also exploring ways to combine PGS with other “omics” data – such as proteomics (the study of proteins) and metabolomics (the study of metabolites) – to create more comprehensive risk profiles.

What Comes Next: A Gradual Integration

The path forward for PGS in glaucoma care involves a series of procedural steps. Further validation studies are needed to confirm the clinical utility of existing scores and to assess their performance in diverse populations. These studies will likely involve prospective cohorts, where individuals are followed over time to observe if their PGS accurately predicts their risk of developing glaucoma. Regulatory bodies may also need to establish guidelines for the apply of PGS in clinical practice, ensuring that they are used responsibly and ethically.

Expect to see a gradual integration of PGS into routine clinical care, starting with specialized glaucoma clinics and research centers. As the technology matures and becomes more affordable, it may become more widely available. The goal is to leverage the power of genomics to provide more personalized and effective care for individuals at risk of glaucoma, preserving their vision and improving their quality of life.